MetaVia Q3: $8.8M Cash Into 1Q 2027, Net Loss $4.6M, Phase 2 MetALD Set for 2H 2027
MTVA sits 45% above its 52-week low of $0.966.
Summary
MetaVia reported a $4.6M third-quarter net loss and $8.8M of cash it says lasts into 1Q 2027, while restating the DA-1726 data already released this month. The 2027 Phase 2 programs depend on raising more money.
Key Events · Earnings and Guidance · MTVA
-
Q3 Loss and Cash Position
For the quarter ended September 30, 2026, the net loss was $4.6M, or $0.69 per share, on 6,679,250 weighted average shares. Cash and cash equivalents stood at $8.8M, down from $10.3M at December 31, 2025.
-
Runway Ends Before Phase 2 Starts
Management states expected cash runway into 1Q 2027, while the 48-week Phase 2 in MetALD/ALD is targeted for 2H 2027 and the vanoglipel combination Phase 2a for 1H 2027. The filing states the 2027 clinical programs are contingent on additional financing.
-
Expenses Rising on DA-1726 Work
R&D rose to $2.6M in Q3 2026 from $1.9M a year earlier, driven by higher direct DA-1726 development costs. Total operating expenses were $4.7M versus $3.5M.
-
Warrant Overhang at $7.94 Strike
Against 6,742,889 common shares outstanding and 15,919,961 fully diluted, 8,947,282 warrants carry a $7.94 weighted-average exercise price. The company states there are no ratchets, price resets or anti-dilution provisions.
Analysis · MTVA · Life Sciences
The clinical story was already public: the 68.1% liver fat and 13.5% weight reductions came in the 2026-11-05 8-K, and the uric acid data on 2026-11-12. What is new here is the money. A $4.6M third-quarter net loss and $8.8M of cash that management says funds operations only into 1Q 2027 sit against a plan that now includes a 48-week Phase 2 in MetALD/ALD starting in the second half of 2027 and a vanoglipel combination Phase 2a in the first half. That gap is the whole story. The company explicitly states the 2027 clinical programs are contingent on additional financing, and it already has 8.9M warrants outstanding at a $7.94 weighted-average strike versus a $1.40 stock price, so a raise would come at a steep cost to current holders. With 6.74M shares outstanding against 15.92M fully diluted, any equity financing lands on a small base.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTVA was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $0.97 to $13.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.